RHBDF1 Knockout A-549 Cell Line
Cat.No.:
EDC07968
Species:
Human
Cell Name:
A-549
Gene:
RHBDF1
Gene ID:
64285
Size:
1×10⁶cells
RHBDF1 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07968 |
|---|---|
| Product Name | RHBDF1 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | RHBDF1 |
| NCBI Gene ID | |
| Gene Synonyms | C16orf8|Dist1|EGFR-RS|gene-89|gene-90|hDist1 |
| Summary |
Predicted to enable growth factor binding activity and serine-type endopeptidase activity. Involved in several processes, including negative regulation of protein secretion; regulation of epidermal growth factor receptor signaling pathway; and regulation of proteasomal protein catabolic process. Located in Golgi membrane and endoplasmic reticulum membrane. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying RHBDF1 function, RHBDF1 Knockout A-549 Cell Line or RHBDF1 overexpression A-549 Cell Line?
The choice depends on whether you are studying RHBDF1 (iRhom1)'s role in lung cancer EGFR ligand shedding or its emerging functions in NSCLC biology. The Knockout line is appropriate for asking whether iRhom1 is required for ADAM17-mediated shedding in lung cancer contexts — iRhom1 may be the dominant iRhom in lung epithelial cells in many tissue contexts. Overexpression is useful for studying iRhom1 in lung cancer progression and EGFR autocrine loops.
For lung cancer research, the EDITGENE RHBDF1 Knockout in A-549 enables study of iRhom1's contribution to lung cancer EGFR ligand shedding in an NSCLC context. This product complements the parallel RHBDF1 Knockout in HEK293 and the RHBDF1 & RHBDF2 Double Knockout in A-549; the lung cancer context is preferred for disease-relevant studies. Rescue with wild-type or non-functional iRhom1 variants enables comprehensive structure-function studies.
What are the application scenarios for this model?
Primary applications:
• Lung cancer EGFR shedding: EGFR ligand release analysis in NSCLC context — iRhom1 may be the dominant iRhom in lung epithelial cells.
• Tumor cell-intrinsic shedding: contribution of iRhom1-mediated shedding to autocrine signaling versus tumor-microenvironment-derived effects.
• iRhom1 versus iRhom2 in lung cancer: side-by-side comparison with parallel RHBDF2 Knockout in A-549 reveals paralog-specific contributions.
• Combined analysis: synergy with the RHBDF1 & RHBDF2 Double Knockout in A-549 for complete iRhom-ADAM17 disruption studies.
EDITGENE recommends this A-549-based model for tumor cell-intrinsic iRhom1 functions in lung cancer; HEK293 parallel knockout is preferred for biochemistry.
Is this RHBDF1 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. iRhom1 rescue in A-549 is well-suited for lung cancer EGFR pathway research:
• Construct design: use a codon-modified RHBDF1 sequence with a small C-terminal tag (FLAG, HA). Preserve the 7-transmembrane rhomboid family architecture.
• Lung cancer-relevant rescue: assessment of iRhom1's contribution to lung cancer EGFR ligand shedding through wild-type or non-functional iRhom1 rescue.
• Paralog comparison: side-by-side rescue analysis with parallel iRhom2 rescue (in RHBDF2-null A-549) reveals paralog-specific contributions in identical lung cancer background.
• Functional readout: rescue should restore ADAM17 maturation, EGFR ligand shedding, and EGFR autocrine signaling phenotypes.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download